Femasys inc. reports encouraging promotional launch of femcerv at aagl based on positive reception by gynecologic physicians and surgeons

--femcerv ® , the first endocervical tissue sampler of its kind in the detection of cervical cancer, was well-received after being presented at the aagl conference attended by over 2,000 leading gynecologic specialists-- atlanta, dec. 12, 2022 (globe newswire) -- femasys inc. (nasdaq: femy), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today reported that it held a promotional launch of its diagnostic product, femcerv®, the first endocervical tissue sampler designed to improve tissue quality and quantity at the annual meeting of aagl (formerly known as the meeting of the american association for gynecologic laparoscopists), where the product was very well received by gynecologic physicians and surgeons. the annual aagl meeting gathers laparoscopic surgeons worldwide dedicated to the research and advancement of minimally invasive gynecologic procedures.
FEMY Ratings Summary
FEMY Quant Ranking